CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour' approach to tumour host interaction in colorectal cancer by Lugli, A et al.
CD8þ lymphocytes/tumour-budding index: an independent
prognostic factor representing a ‘pro-/anti-tumour’ approach to
tumour host interaction in colorectal cancer
A Lugli
1, E Karamitopoulou
2, I Panayiotides
2, P Karakitsos
3, G Rallis
4, G Peros
4, G Iezzi
5, G Spagnoli
5, M Bihl
1,
L Terracciano
1 and I Zlobec*,1
1Institute of Pathology, University of Basel, Scho ¨nbeinstrasse 40, Basel 4031, Switzerland;
2Second Department of Pathology, Attikon University Hospital,
Rimini 1, Haidari, Athens 12464, Greece;
3Department of Diagnostic Cytopathology, Attikon University Hospital, Rimini 1, Haidari, Athens 12464,
Greece;
4Fourth Department of Surgery, Attikon University Hospital, Rimini 1, Haidari, Athens 12464, Greece;
5Institute for Surgical Research and
Hospital Management, University of Basel, Hebelstrasse 20, Basel 4031, Switzerland
BACKGROUND: The tumour-host interaction at the invasive front of colorectal cancer, including the epithelial–mesenchymal transition
and its hallmark ‘tumour budding’, is an important area of investigation in terms of prognosis. The aim of this study was to determine
the prognostic impact of a ‘pro-/anti-tumour’ approach defined by an established ‘pro-tumour’ (tumour budding) and host-related
‘anti-tumour’ factor of the adaptive immunological microenvironment (CD8þ lymphocytes).
METHODS: Double immunostaining for CK22/CD8 on whole tissue sections (n¼279; Cohort 1) and immunohistochemistry for
CD8þ using tissue microarrays (n¼191; Cohort 2) was carried out. Tumour buds, CD8þ and CD8þ T-lymphocytes:tumour
buds indices were evaluated per high-power field.
RESULTS: In Cohort 1, a low-CD8þ/buds index was associated with lymph node metastasis (Po0.001), vascular invasion (P¼0.009),
worse survival in univariate (Po0.001) and multivariable (Po0.001) analysis, and furthermore in lymph node-negative patients
(P¼0.002). In Cohort 2, the CD8þ/buds index was associated with T stage (Po0.001), N stage (P¼0.041), vascular invasion
(P¼0.005) and survival in patients with TNM stage II (P¼0.019), stage III (P¼0.004), and adjuvantly untreated (P¼0.009) and
treated patients (Po0.001).
CONCLUSION: The CD8þ lymphocyte:tumour-budding index is an independent prognostic factor in colorectal cancer and a
promising approach for a future prognostic score for patients with this disease.
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During the Napoleonic Wars (1796–1815), one of the most
effective methods to attack in battle was the deployment of heavy
cavalry, which the opponent tried to repel by organizing the
infantry into squares.
A similar picture can be observed at the invasion front of colorectal
cancer. On one hand, the tumour mass invades the pericolic fat tissue,
detaching clusters or single tumour cells (tumour buds) reflecting
tumour progression; whereas, on the other hand the host attempts to
confront this situation by building an ‘anti-tumour’ cytotoxic
inflammatory response. This ‘pro-/anti-tumour’ model is supported
by a range of studies proposing either independent tumour-related
prognostic factors (pro-tumour), such as tumour grade, tumour
border configuration, medullary subtype, CEA level, microsatellite
instability, loss of heterozygosity (LOH) 18q status, p53 levels, TGFB1
type II receptor levels, VEGF expression, proliferation rate and
metalloproteinase expression (Compton, 2006) or anti-tumour
factors, such as CD3þ,C D 4 þ,C D 8 þ,C D 2 0 þ lymphocytes,
Granzyme B, FoxP3þ regulatory T cells (Tregs), CD16þ cells, and
mast and dendritic cells (Dadabayev et al,2 0 0 4 ;P h i l l i p set al, 2004;
Sato et al, 2005; Chaput et al,2 0 0 9 ;S a l a m aet al, 2009).
Consequently, several groups focus on the invasive front of
colorectal cancer using the term epithelial–mesenchymal transi-
tion (EMT), which characterises tumour invasion by de-differ-
entiated colorectal carcinoma cells (Brabletz et al, 2005). EMT and
MET, the reverse transition from a mesenchymal to an epithelial
phenotype, are crucial steps not only in embryonic development
but also in tumour progression (Spaderna et al, 2007).
A histomorphological hallmark of EMT is the phenomenon of
‘tumour budding’ (Prall, 2007), which according to the third
edition of ‘Prognostic Factors in Cancer’ published by the UICC in
2006, is considered an additional prognostic factor in colorectal
cancer (Compton, 2006). A tumour bud is typically defined as a
single tumour cell or tumour cell cluster of up to five cells at the
invasive tumour front (Prall, 2007). Indeed, tumour budding has
been shown to be associated with lymph node positivity, poorly
differentiated tumours, presence of vascular and lymphatic
invasion, local tumour recurrence and distant metastasis (Ueno
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set al, 2004a,b; Nakamura et al, 2005; Kazama et al, 2006; Ishikawa
et al, 2008; Wang et al, 2009). In particular, patients with stage III
disease have been reported to demonstrate a 5-year disease-free
survival (DFS) of 62.1% in the absence of tumour budding and
only a 35.1% DFS with this feature (Choi et al, 2007). Moreover,
the presence of tumour budding has repeatedly been linked to
poor clinical outcome, underlined by the adverse effect on overall
survival independent of TNM stage (Hase et al, 1993; Ueno et al,
2004b).
Over the last 20 years, investigations on tumour immunity and
host defence in colorectal cancer demonstrate promising results
for immunotherapy. In most colorectal cancers, lymphocytic
infiltration is composed predominantly of either CD4þ or
CD8þ T cells and both cell types appear to be significantly
increased in tumour as compared with normal tissue (Ropponen
et al, 1997; Naito et al, 1998; Chiba et al, 2004; Koch et al, 2006).
Several studies have shown that tumour infiltrating lymphocytes
(TILs) within the stroma and around the tumour along the
invasive margin are significantly related to overall- and disease-
specific survival in both univariate and multivariable analysis (Ali
et al, 2004; Canna et al, 2005; Pages et al, 2005). Galon et al (2006)
evaluated by gene-expression profiling and immunohistochemis-
try, the type, density and location (whether at the invasive margin
or the tumour centre) of TILs in a large number of cases. They
evaluated CD3, CD8, granzyme B and memory CD45RO T cells,
demonstrating a significant independent and positive effect of
TILs on both recurrence and survival.
In colorectal cancer, mismatch-repair status (microsatellite
stable (MSS) and microsatellite instability-high (MSI-H)) seems
to relate highly to the number of CD8þ lymphocytes. Compared
with MSS tumours, MSI-H cancers are characterised by prolonged
survival time, significantly more frequent peritumoural lympho-
cytic infiltration at the invasive front and by an inherent
abundance of intra-epithelial TILs (Jass et al, 1998; Michael-
Robinson et al, 2001; Greenson et al, 2003; Jenkins et al, 2007).
Nevertheless, many studies analyzing colorectal cancer samples
stratified by mismatch-repair status also report a positive effect of
CD8þ lymphocytes in mismatch-repair proficient colorectal
cancers (Baker et al, 2007).
Although this wide range of possible additional prognostic factors
in colorectal cancer is currently being investigated, still missing is an
approach to include parameters reflecting the tumour dynamics. Such
an approach has already been taken for the prognostication of breast
cancer, namely the Bloom–Richardson–Elston (BRE) score, which
encompasses information on mitoses, tubule differentiation and
nuclear pleomorphism, and is used as an important prognostic
feature additional to TNM staging.
Therefore, the aim of this study was to investigate on a potential
‘pro-/anti-tumour’ model and to test the prognostic impact of
a ratio defined by an established pro-tumour (tumour budding)
and anti-tumour (CD8þ lymphocytes) factor. To this end, two
independent colorectal cancer patient cohorts from different
centres were investigated using two different approaches, namely
whole tissue sections (n¼300) and the tissue microarray
technique (n¼221).
MATERIALS AND METHODS
Cohort 1-Whole tissue sections
Sample size determination To reach 85% power with an expected
risk ratio of 1.8 between prognostic groupings and potential
loss of patient samples in 10% of cases the appropriate sample
size for this study was determined to be 255 cases. Owing to the
availability of material this number was increased to 300 cases.
Specimens: Paraffin-embedded tissue blocks of 300 resection
specimens of patients treated between 1987 and 1996 at the
University Hospital of Basel were retrieved from the archives of
the Institute of Pathology, University Hospital of Basel, as well
as at the Institute of Clinical Pathology, Basel, Switzerland. These
300 cases were randomly selected from a larger previously
described cohort of 938 colorectal cancer patients with full
clinico-pathological information (Zlobec et al, 2008). The use of
material for this study was approved by the local research ethics
committee.
Double immunostaining for CD8 and CK22 A double immuno-
staining procedure using anti-CD8 (for detection of CD8þ
T-lymphocytes) and pan-cytokeratin (to facilitate visualization
of tumour buds at the invasive front) was carried out on one
representative slide cut at 4mm from paraffin-embedded tumour
blocks of all 300 colorectal cancer patients included in this study
(Figure 1). Double staining was carried out using the BOND-MAX
Automated Immunohistochemistry Vision Biosystem (Leica
Microsystems GmbH, Wetzlar, Germany) according to the
following protocol. First, tissues were deparaffinised and pre-
treated with the Epitope Retrieval Solution 2 (EDTA-buffer pH8.8)
at 1001C for 20min. After wash steps, peroxidase blocking was
carried out for 10min using the Bond Polymer Refine Detection
Kit DC9800 (Leica Microsystems GmbH). Tissues were again
washed, then incubated with primary antibody against CK22
(Biomeda, Foster City, CA, USA, pan-CK22) for 30min. Subse-
quently, tissues were incubated with polymer for 15min and then
Figure 1 Double immunostaining for CD8 (red) and CK22 (brown): (A) Overview ( 10) and (B) high power field ( 40) of the invasive front of
colorectal cancer showing CK22 positive tumour buds surrounded by CD8þ T-lymphocytes.
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swith DAB-Chromogen for 10min (Bond Polymer AP Red
Detection Kit DS9305, Leica Microsystems GmbH). CK22 positive
cells were therefore coloured in brown. After washing, incubation
was carried out with anti-CD8 (DakoCytomation, Glostrup,
Denmark, clone CD8/144B) for 30min followed by application of
AEC-substrate for 10min and counterstaining with haematoxylin
for 2min.
Evaluation of tumour buds and CD8þ T-lymphocytes Tumour
budding was defined as an isolated single cancer cell or a cluster
of up to five cells at the invasive front of colorectal cancer
(Prall, 2007). The tumour border was scanned at a  100
magnification and the area of most intense budding was identified
(Ueno et al, 2002). After selecting this field, the number of buds
was counted using a 40  objective lens to focus specifically
on the presence of CD8þ T-cells most highly related to the
microenvironment surrounding the tumour buds. Within this
same field, all CD8þ lymphocytes were individually counted. In
10 cases, the abundance of CD8þ infiltrate led to cell counts
exceeding 200 cells per field, and thus single cell counting was
not feasible. These cases were assigned a CD8þ score of 200 cells.
The ratio of CD8þ T-lymphocytes to the number of tumour
buds (CD8þ/buds index) was obtained. In 13 cases when zero
buds were identified, the count of CD8þ lymphocytes was not
carried out.
Clinico-pathological characteristics Of these 300 cases, 279 were
evaluable for CD8 and CK22 protein expression, simultaneously.
Hematoxylin and eosin (H&E) stained slides were reviewed
and histomorphological data included histological subtype, pT
stage, pN stage and tumour grade. The tumour border configura-
tion and the presence of conspicuous peritumoural lymphocytic
infiltration were defined according to Jass et al (1986). Clinical
data were retrieved from patient records and included age at
diagnosis, gender, tumour location and follow up. Clinical
outcome of interest was disease-specific survival time, which was
available for all 279 patients. Median follow-up time was 60
months. In all, 128 patients died of disease. Patient characteristics
are listed in Table 1.
Microsatellite instability (MSI) status, KRAS and BRAF gene
status Genomic DNA was obtained from primary tumours
using NucleoMag 96 Tissue Kit (Macherey Nagel, Oensingen,
Switzerland) protocol and processed in the Xiril X-100 robot (Xiril,
Hombrechtikon, Switzerland). Briefly, punched tissue was lysed in
proteinase K. B-beads and MB2 buffer were added to the cleared
lysate and shaken for 5min at room temperature. The supernatant
was removed and MB3 was added followed by shaking and
supernatant removal. The genomic DNA was eluted with MB6
buffer. Genomic DNA was amplified by PCR using AmpliTaq Gold
polymerase (Applied Biosystem, Foster City, CA, USA). KRAS
(exon 2, codon 12 and 13) and BRAF (exon 15, codon 600) were
amplified by a first and a nested PCR. Residual primers
were removed using the EXOSAPit (Amersham, Otelfingen,
Switzerland). Samples were then subjected to direct sequencing
of single-stranded PCR products using the BigDye Terminator v1.1
cycle sequencing kit (Applied Biosystems) and the ABI Prism 3130
genetic analyser (Applied Biosystems). All products were se-
quenced bi-directionally. Analysis of MSI status was based on the
multiplex amplification of the five microsatellites (BAT25, BAT26,
D2S123, D5S346 and D17S250). An initial denaturation step at
951C for 10min was followed by 42 cycles at 951C for 40s, 541C for
40s and 721C for 60s. For the analysis, 1ml of the DNA weight
marker ROX 500 (Applied Biosystem) was added and 10ml
of deionised formamide in 3ml of the PCR amplified solution.
DNA was denaturated by incubation for 2min at 951C. The
POP-7 polymer solution (Applied Biosystem) was used for
the electrophoresis on the ABI Prism 3130 genetic analyser
(Applied Biosystems). MSS and MSI-low (MSI-L) status were
defined as instability at zero and one markers, respectively. MSI-H
was characterised by the presence of instability in two or more
markers (Umar et al, 2004).
Table 1 Characteristics of patients in Cohort 1 (n¼279)
Clinico-pathological features Frequency N (%)
Age (years) (n¼279)
Mean, range 67.7, 37–96
Tumour diameter (mm) (n¼279)
Mean, range 54.0, 13–170
Gender (n¼279)
Male 122 (43.7)
Female 157 (56.3)
Tumour location (n¼279)
Left-sided 71 (25.4)
Right-sided 111 (39.8)
Rectum 97 (34.7)
Histological subtype (n¼277)
Adenocarcinoma 252 (91.0)
Mucinous 21 (7.6)
Other 4 (1.4)
pT stage (n¼274)
pT1 6 (2.2)
pT2 35 (12.8)
pT3 187 (68.3)
pT4 46 (16.8)
pN stage (n¼273)
pN0 140 (51.3)
pN1 76 (27.8)
pN2 57 (20.9)
Tumour grade (n¼274)
G1 5 (1.8)
G2 247 (90.2)
G3 22 (8.0)
Vascular invasion (n¼274)
Absent 206 (75.2)
Present 68 (24.8)
Tumour border configuration (n¼271)
Infiltrating 186 (68.6)
Pushing 85 (31.4)
Peritumoural lymphocytic infiltration (n¼274)
Absent 204 (74.5)
Present 70 (25.6)
Microsatellite instability status (n¼125)
Stable/low 95 (76.0)
Instable/high 30 (24.0)
KRAS gene status (n¼117)
Wild-type 82 (70.1)
Mutation 35 (29.9)
BRAF gene status (n¼106)
Wild-type 85 (80.2)
Mutation 21 (19.8)
5-year survival (%) (n¼279)
Rate (95%CI) 60.3 (54–66)
Continuous variables age and tumour diameter are described as the mean and range
of values, whereas categorical variables are represented by the number of cases (% of
cases). Survival time was obtained using the Kaplan–Meier method.
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sCohort 2-Tissue microarray
Colorectal cancer tissue microarray construction At i s s u em i c r o -
array of 221 unselected, non-consecutive colorectal cancer patients
treated at the Second Department of Pathology, University of Athens
between the years 2004 and 2006 was constructed at the Institute for
Pathology, University Hospital of Basel. The use of this material was
approved by the local ethics committee of the University of Athens.
Each patient had multiple tissue punches taken from formalin-fixed,
paraffin-embedded blocks using a tissue cylinder with a diameter of
0.6mm, which were subsequently transferred into one recipient
paraffin block (3 2.5cm
2)u s i n gah o m e m a d es e m i - a u t o m a t e dt i s s u e
arrayer. Tissues were obtained from the tumour centre, the invasive
tumour front within the representative area of most intense tumour
budding in all sections of the tumour, as determined from
corresponding H&E slides, the normal adjacent mucosa (if available)
and the transitional zone where tumour and normal adjacent mucosa
first interact (if available). Each patient on average had 5.1 tissue
punches included on this array. The final tissue microarray contained
1079 tissues, namely 437 tissues from the tumour centre, 430 from the
invasive front, 90 from normal adjacent mucosa and 122 from the
transitional zone. For the purposeso ft h i ss t u d y ,o n l yt i s s u ep u n c h e s
from the invasive tumour front per patient were analysed.
Clinico-pathological features H&E slides were reviewed and
histomorphological data included histological subtype, pT stage,
pN stage, pM stage, tumour grade, and vascular and lymphatic
invasion. Clinical data were retrieved from patient records and
included age at diagnosis, gender, tumour location and follow up.
Information on adjuvant therapy was available for all patients.
Patients with TNM stage IV disease were removed from this study,
thus 191 patients with stage I–III disease constituted the final
patient cohort. Clinical outcome of interest was disease-specific
survival time, which was available for all 191 patients. Median
follow-up time is 35 months and 44 patients died of the disease.
Patient characteristics are listed in Table 2.
Immunohistochemistry Immunohistochemistry was carried out
u s i n ga n t i - C D 8a n t i b o d ya tt h eS e c o n dD e p a r t m e n to fP a t h o l o g y ,
University of Athens. Briefly, 5-mm TMA sections were deparaffinised,
and pre-treated with the Envision FlexT a r g e tR e t r i e v a lS o l u t i o np H 8 . 8
(DM812, Dako) at 8001C for 6min followed by incubation at room
temperature for 10min. After wash steps, peroxidase blocking was
carried out for 10min. Sections were again washed and then incubated
with primary antibody against CD8 (DakoCytomation; clone CD8/
144B) for 60min. Subsequently, sections were washed with TBS and
incubated with Real Envision Solution (Dako) for 30min, then washed
again in TBS and incubated with DAB-Chromogen for 10min. After
washing, sections were counterstained with haematoxylin for 2min.
Only peritumoural CD8þ T-lymphocytes in punches taken from the
invasive tumour front were counted.
Cut-off score for low vs high budding, CD8þ and CD8þ/buds
indices All cut-off scores to classify patients as having a ‘low’ or
‘high’ index were obtained by receiver operating characteristic
curve (ROC) analysis (Zlobec et al, 2007b). 50% of the data was
randomly selected for this purpose. Using this method, a plot of
the sensitivity and false positive rate (1-specificity) for discrimi-
nating between survivors and non-survivors was assessed. The
most discriminating cut-off score was determined as the point on
the ROC curve with the shortest distance to the coordinate (0, 1),
namely with the maximum sensitivity and specificity for survival.
The reliability of all cut-off scores was tested by re-sampling of the
data (500 bootstrapped replications). The discriminatory ability of
each feature for survival was also evaluated by analyzing the area
under the ROC curve (AUC) and 95% confidence interval (CI).
Additional statistical analyses The association of indices with
categorical clinico-pathological features was obtained using the
w
2 and Fisher’s exact tests, where appropriate. Univariate survival
analysis was carried out using the Kaplan–Meier and log-rank
tests. Multivariable analysis was carried out using Cox’s propor-
tional hazards regression analysis after the verification of
proportional hazards assumption. Hazard ratio (HR) and 95%CI
were obtained to determine the prognostic effect of each index
after adjustment. With logistic regression analysis, the odds ratios
(OR) and 95%CI were obtained to determine the odds of death at
5 years with the use of different indices. All statistical analyses
were carried out using SAS (V9, The SAS Institute, NC, Cary, USA).
RESULTS
Cohort 1-Whole tissue sections
Tumour-budding index A high tumour-budding index was
defined, using ROC curve analysis, as at least 16 buds per  40
Table 2 Characteristics of patients in Cohort 2 (n¼191)
Frequency N (%)
Age (years) (n¼184)
Mean, range 67.9 (35–93)
Tumour diameter (mm) (n¼189)
Mean, range 4.6 (1.0–12.0)
Gender (n¼189)
Male 88 (46.6)
Female 101 (53.4)
Tumour location (n¼190)
Left-sided 113 (59.5)
Right-sided 27 (14.2)
Rectum 50 (26.3)
Histological subtype (n¼189)
Mucinous 24 (12.7)
Other 165 (87.3)
pT stage (n¼189)
pT1–2 52 (27.5)
pT3–4 137 (72.5)
pN stage (n¼189)
pN0 102 (54.0)
pN1–2 87 (46.0)
TNM stage (n¼189)
Stage I 45 (23.8)
Stage II 57 (30.2)
Stage III 87 (46.0)
Tumour grade (n¼189)
G1–2 122 (64.6)
G3 67 (35.5)
Vascular or lymphatic invasion (n¼191)
Absent 147 (91.1)
Present 17 (8.9)
Adjuvant therapy (n¼191)
None 69 (36.1)
Treated 122 (63.9)
5-year survival (%) (n¼191)
Rate (95%CI) 67.5 (57–76)
Continuous variables age and tumour diameter are described as the mean and range
of values, whereas categorical variables are represented by the number of cases (% of
cases). Survival time was obtained using the Kaplan–Meier method.
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sfield (Figure 2A). However, the ROC curve also highlights a
relatively poor discrimination of survivors and non-survivors at
5-year follow up with an AUC value of 0.59 (95%CI: 0.52–0.67).
A high-budding index was significantly associated with a more
advanced pT stage (P¼0.017), with the presence of lymph node
metastasis (P¼0.002), with the presence of vascular invasion
(P¼0.028) and with an infiltrating tumour border configuration
(P¼0.005) (Table 3). Patients with MSI-H cancers were signifi-
cantly less prone to a high tumour-budding index (P¼0.022),
whereas no association was observed with KRAS or BRAF
mutation. The odds of death from disease at 5 years in the group
with a high-budding index was OR (95%CI)¼1.89 (1.1–3.3)
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Figure 2 Cohort 1. (A, C and E): Receiver operating characteristic (ROC) curves highlighting the ability of tumour budding (A), CD8þ lymphocytes
(C) and CD8þ/buds index (E) to discriminate survivors and non-survivors. AUC¼area under the ROC curve. Larger the AUC, more discriminating
the feature. Arrows are drawn from the point on the curve used to classify patients into ‘low’ or ‘high’ indices based on their proximity to the coordinate
(0,1). (B, D and F) corresponding Kaplan–Meier survival curves for ‘low’ and ‘high’ indices.
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5-year disease-specific survival rate of patients with high and low
tumour-budding index was 53.0 (95%CI 42–63) and 63.9 (95%CI
57–70), suggesting a significantly worse prognosis in patients with
high tumour-budding index (P¼0.033) (Figure 2B). In patients
with MSS/MSI-L tumours, a high-budding index was related to
more advanced pT stage (P¼0.019), pN stage (P¼0.002), vascular
invasion (P¼0.004) and an infiltrating tumour border configu-
ration (P¼0.021) and worse survival in univariate analysis
(P¼0.02). In MSI-H patients, the high tumour-budding index
was only related to an infiltrating tumour border configuration
(P¼0.015).
Table 3 Association of budding index, CD8+ index and CD8þ/buds index with clinico-pathological features – Cohort 1 (n¼279)
Budding index CD8+ index CD8+/buds index
Clinico-pathological feature Low High P-value Low High P-value Low High P-value
Gender
Female 107 (56.9) 50 (55.0) 0.797 61 (54.0) 87 (57.2) 0.598 72 (54.1) 85 (58.2) 0.492
Male 81 (43.1) 41 (45.1) 52 (46.0) 65 (42.8) 61 (45.9) 61 (41.8)
Tumour location
Left-sided 48 (25.5) 23 (25.3) 0.06 30 (26.5) 37 (40.7) 0.551 34 (25.6) 37 (25.3) 0.053
Right-sided 82 (43.6) 29 (31.9) 42 (37.2) 62 (40.8) 45 (33.8) 66 (45.2)
Rectum 58 (30.9) 39 (42.9) 41 (36.3) 53 (34.9) 54 (40.6) 43 (29.5)
pT stage
pT1–2 34 (18.6) 7 (7.7) 0.017 15 (13.5) 20 (13.4) 0.983 15 (11.4) 26 (18.3) 0.107
pT3–4 149 (81.4) 84 (92.3) 96 (86.5) 129 (86.6) 117 (88.6) 116 (81.7)
pN stage
pN0 106 (57.9) 34 (37.8) 0.002 50 (45.5) 81 (54.4) 0.156 53 (40.5) 87 (61.3) o 0.001
pN1–2 77 (42.1) 56 (62.2) 60 (54.6) 68 (45.6) 78 (59.5) 55 (38.7)
Tumour grade
G1–2 166 (90.7) 86 (94.5) 0.276 104 (63.7) 135 (90.6) 0.366 125 (94.7) 127 (89.4) 0.109
G3 17 (9.3) 5 (5.5) 7 (6.3) 14 (9.4) 7 (5.3) 15 (10.6)
Vascular invasion
Absent 145 (79.2) 61 (67.0) 0.028 79 (71.2) 115 (77.2) 0.271 90 (68.2) 116 (81.7) 0.009
Present 38 (20.8) 30 (33.0) 32 28.8) 34 (22.8) 42 (31.8) 26 (18.3)
Tumour border configuration
Infiltrating 114 (63.0) 72 (80.0) 0.005 80 (73.4) 102 (68.9) 0.435 100 (76.9) 86 (61.0) 0.005
Pushing 67 (37.0) 18 (20.0) 29 (26.6) 46 (31.1) 30 (23.1) 55 (39.0)
Peritumoural lymphocytic inflammation
Absent 137 (74.9) 67 (73.6) 0.825 93 (83.8) 100 (67.1) 0.002 108 (81.8) 96 (67.6) 0.007
Present 46 (25.1) 24 (26.4) 18 (16.2) 49 (32.9) 24 (18.2) 46 (32.4)
KRAS gene status
Wild-type 55 (75.3) 27 (61.4) 0.11 31 (64.6) 47 (74.6) 0.253 38 (64.4) 44 (75.9) 0.176
Mutation 18 (24.7) 17 (38.6) 17 (65.4) 16 (25.4) 21 (35.6) 14 (24.1)
BRAF gene status
Wild-type 54 (77.1) 31 (86.1) 0.273 36 (90.0) 45 (75.0) 0.063 41 (85.4) 44 (75.9) 0.219
Mutation 16 (22.9) 5 (13.9) 4 (10.0) 15 (25.0) 7 (14.6) 14 (24.1)
Microsatellite instability status (MSS)
MSS/MSI-L 54 (69.2) 41 (87.2) 0.022 43 (86.0) 47 (69.1) 0.033 51 (83.6) 44 (68.8) 0.052
MSI-H 24 (30.8) 6 (12.8) 7 (14.0) 21 (30.9) 10 (16.4) 20 (31.2)
Survival rate (%) (95% CI)
5-year 63.9 (57–70) 53.0 (42–63) 0.033 47.2 (38–56) 67.9 (60–75) o 0.001 46.6 (38–55) 72.8 (65–79) o 0.001
Table 4 Comparison of the discriminatory ability of each feature for identifying survivors and non-survivors at 5-year follow up
Feature Sensitivity Specificity Overall accuracy (95% CI) OR (95% CI) P-value
Budding count (high vs low) 0.413 0.737 0.59 (0.52–0.67) 1.89 (1.1–3.3) 0.022
CD8+ count (low vs high) 0.597 0.683 0.64 (0.59–0.7) 3.18 (1.8–5.5) o0.001
CD8:buds index (low vs high) 0.721 0.61 0.68 (0.61–0.75) 4.12 (2.4–7.1) o0.001
Odds ratio (OR) indicate that the odds of disease-specific death at 5-years is 1.89 times higher in the high-budding count group compared with the low group; for CD8+ count,
3.18 times higher in the low compared with the high CD8+ count group and for the CD8:buds index, is 4.12 times higher in those with a low compared with a high index.
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presence of at least 40 CD8þ cells per  40 field (Figure 2C). The
discriminatory ability of CD8þ as indicated by the AUC was 0.64
(95%CI 0.59–0.7), suggesting an improvement compared with the
budding index alone. The odds of death from disease at 5 years
was OR (95%CI)¼3.18 (1.8–5.5) in patients with a low compared
with a high CD8þ index. A high CD8þ index was associated
with significantly more frequent peritumoural lymphocytic inflam-
mation at the tumour front (P¼0.002), with MSI-H status
(P¼0.033) and marginally with BRAF mutation. Patients with
a high CD8þ index demonstrated a significantly prolonged
survival time compared with those with a low CD8þ index
(Po0.001) (Figure 2D). In MSS/MSI-L and MSI-H patients, the
CD8þ index was not linked to any features of tumour progression
although in MSS/MSI-L those with a high CD8þ index
experienced a significant prolonged survival time (P¼0.011).
CD8þ/buds index A ratio of at least three times more
CD8þ T-cells vs the number of tumour buds led to a strong
discrimination of survivors and non-survivors of colorectal cancer,
as indicated by an AUC value of 0.68 (95%CI 0.61–0. 75)
(Figure 2E). The odds of death at 5 years in patients with a low
CD8þ/buds index compared with those with a high index was
OR (95%CI)¼4.12 (2.4–7.1) indicating that on average the odds
of death was 4.12 times greater in patients with a low compared
with a high CD8þ/buds index (Table 4). Patients with a high
CD8þ/buds index demonstrated more favourable features, such
as early T stage (Po0.001), absence of vascular invasion
(P¼0.009), presence of a pushing/expanding tumour border
configuration (P¼0.005), presence of peritumoural lymphocytic
inflammation at the invasive front (P¼0.007) and a marginal
association with MSI-H status (P¼0.052). Most notably, a
considerable difference in survival time between patients with
low and high CD8þ/buds index was observed with patients with a
low index demonstrating a highly adverse prognosis (Po0.001)
(Figure 2F). This prognostic difference was also maintained in the
group of MSS/MSI-L patients (P¼0.001).
Independent prognostic effects of budding, CD8þ and CD8þ/
buds indices A comparison of the performance of each of these
indices in multivariable survival analysis is outlined in Table 5.
The effect of each of these factors was re-evaluated along with age,
gender, pT stage, pN stage, tumour grade, vascular invasion and
the tumour border configuration. Analysis was thus carried out
only for patients with complete clinico-pathological information
for all these features (n¼226, 101 deaths). The budding index was
not found to add independent prognostic information when
analysed along with these additional features (P¼0.85), whereas
the CD8þ index (Po0.001) and the CD8þ/buds index
(Po0.001) were highly relevant as prognostic factors in multi-
variable analysis, with similar relative risks of death suggesting a
comparable performance of these two features as prognostic
indices.
In order to prevent over-fitting of multivariable models, only the
most relevant prognostic factors were included into sub-group
analyses of lymph node-negative patients (n¼140, 42 deaths), as
well as of those with colon (n¼176; 79 deaths) or rectal cancers
(n¼94; 44 deaths). In lymph node-negative patients, multivariable
analysis with pT stage, vascular invasion and tumour border
configuration revealed independent prognostic effects for both the
Table 5 Comparison of relative risks of buds, CD8+ and CD8+/buds index in multivariable analysis with age, gender, pT stage, pN stage, tumour grade,
vascular invasion and tumour border configuration in Cohort 1
Buds index only CD8+ index only CD8+/buds index
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Index
Low 1.0 0.85 1.0 o0.001 1.0 o0.001
High 1.04 (0.7–1.6) 0.45 (0.3–0.7) 0.44 (0.3–0.7)
Age (years)
Baseline 1.0 0.041 1.0 0.026 1.0 0.021
Increasing by year 1.02 (1.0–1.1) 1.02 (1.0–1.1) 1.02 (1.0–1.1)
Gender
Male 1.0 0.468 1.0 0.507 1.0 0.443
Female 0.86 (0.6–1.3) 0.87 (0.6–1.3) 0.86 (0.6–1.3)
pT stage
pT1–2 1.0 0.042 1.0 0.048 1.0 0.022
pT3–4 2.41 (1.0–5.6) 2.35 (1.0–5.5) 2.69 (1.2–6.3)
pN stage
pN0 1.0 o0.001 1.0 o0.001 1.0 0.001
pN1–2 2.27 (1.5–3.5) 2.12 (1.4–3.3) 2.06 (1.4–3.2)
Tumour grade
G1–2 1.0 0.205 1.0 0.738 1.0 0.873
G3 0.63 (0.3–1.3) 0.88 (0.4–1.9) 0.94 (0.4–2.0)
Vascular invasion
Absent 1.0 o0.001 1.0 0.001 1.0 0.014
Present 2.2 (1.4–3.5) 2.1 (1.3–3.3) 1.79 (1.1–2.8)
Tumour border configuration
Pushing 1.0 0.758 1.0 0.945 1.0 0.915
Infiltrating 1.09 (0.6–1.8) 1.02 (0.6–1.8) 1.03 (0.6–1.8)
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sCD8þ index (P¼0.001) and the CD8þ/buds index (P¼0.002),
but not for the budding index. Moreover, in patients with colon or
rectal cancer, the CD8þ index (P¼0.015 and P¼0.006, respec-
tively) as well as the CD8þ/buds index (P¼0.002 and P¼0.016,
respectively) maintained a significant independent prognostic
effect after adjusting for pT stage, pN stage and vascular invasion.
Cohort 2-Tissue microarray
In Cohort 2, a high tumour-budding index in stages I–III patients
was defined as at least six buds per punch and was related to a more
advanced pT stage (P¼0.029), more poorly differentiated tumours
(P¼0.003), presence of vascular invasion (P¼0.045) and was highly
related to a worse prognosis (P¼0.003) (Table 6). The threshold
value for a high CD8þ index was 13 cells per punch and was linked
to lymph node negativity (P¼0.053), early tumour grade (P¼0.014),
absence of vascular invasion (P¼0.002) and a prolonged survival
time compared with patients with a low CD8þ index (P¼0.031).
A ratio of three times more CD8þ lymphocytes to the number
of tumour buds was identified as the most discriminating cut-off
value to classify survivors and non-survivors. Patients with a
high CD8þ/buds index had tumours that were more early pT
stage (P¼0.001), lymph node-negative (P¼0.055), early tumour
grade (Po0.001) and vascular invasion negative (P¼0.002). Low
CD8þ/buds index, led to a highly unfavourable prognosis
compared with patients with a high CD8þ/buds index (Po0.001).
This difference was also maintained in sub-group analysis of TNM
stage II (P¼0.019) and stage III (P¼0.004) patients (Figure 3A
and B). In particular, in both untreated and treated patients, a low
CD8þ/buds index was linked to a shorter survival time (P¼0.009
and Po0.001, respectively) (Figure 3B and C). Multivariable analysis
for the budding index, CD8þ index and CD8þ/buds index was
carried out accounting for pN stage, vascular and lymphatic invasion
and treatment effect. Results outlined in Table 7 highlight once more
the independent adverse prognostic effect of a low CD8þ/buds
index after adjusting for these additional factors.
DISCUSSION
The aim of this study was to investigate an alternative approach to
reflect the dynamic at the tumour front of colorectal cancer using
an index including tumour budding and CD8þ lymphocytes.
Briefly summarised, our results confirm the prognostic impact
of the selected tumour and host-related factors. In both patient
cohorts, a high tumour budding and a low CD8þ lymphocytes
index were associated with tumour progression and worse survival.
Indeed, tumour budding has previously been found to be
associated with higher N stage, higher tumour grade and presence
of vascular invasion, local tumour recurrence, distant metastasis as
well as worse survival (Ueno et al, 2004a,b; Nakamura et al, 2005;
Kazama et al, 2006; Prall, 2007; Ishikawa et al, 2008; Wang et al,
2009). There is also strong evidence for an association between a
high number of CD8þ lymphocytes and absence of lymph node
metastases, lower tumour grade, presence of peritumoural
lymphocytes, mismatch repair-deficient status and better survival
(Ropponen et al, 1997; Naito et al, 1998; Chiba et al, 2004; Galon
et al, 2006; Koch et al, 2006; Baker et al, 2007).
The question, therefore, arises as to whether a CD8þ
lymphocytes:budding index is more advantageous over the use
of one out of the two parameters alone. With the exception of
5-year survival, a certain intra- and inter-group variability
is observed when analysing the relationship of tumour budding
or CD8þ lymphocytes with clinico-pathological parameters.
In contrast, the use of a CD8þ lymphocytes:budding index
better summarises these associations with key endpoints of
tumour progression, namely presence of lymph node metastases,
vascular invasion and worse survival, and moreover, in both
cohorts. In addition, the CD8þ/buds index shows an increased
Table 6 Association of budding index, CD8+ index and CD8þ/buds index with clinico-pathological features – Cohort 2 (n¼191)
Budding index CD8+ index CD8+/buds index
Clinico-pathological feature
Low
(n¼131)
High
(n¼60) P-value
Low
(n¼69)
High
(n¼121) P-value
Low
(n¼68)
High
(n¼122) P-value
Gender
Male 65 (50.4) 23 (38.3) 0.122 34 (49.3) 54 (54.4) 0.606 33 (48.5) 55 (45.8) 0.722
Female 64 (49.6) 37 (61.7) 35 (50.7) 65 (54.6) 35 (51.5) 65 (54.2)
Tumour location
Left-sided 80 (61.5) 33 (55.0) 0.311 38 (55.1) 74 (61.7) 0.673 35 (51.5) 77 (63.6) 0.054
Right-sided 20 (15.4) 7 (11.7) 11 (15.9) 16 (13.3) 8 (11.8) 19 (15.7)
Rectum 30 (23.1) 20 (33.3) 20 (16.0) 30 (25.0) 25 (36.8) 25 (20.7)
pT stage
pT1–2 42 (32.3) 10 (17.0) 0.029 15 (21.7) 37 (31.1) 0.167 9 (13.4) 43 (35.5) 0.001
pT3–4 88 (67.7) 49 (83.0) 54 (78.3) 82 (68.9) 58 (86.6) 78 (64.5)
pN stage
pN0 79 (71.2) 23 (67.7) 0.694 30 (60.0) 71 (75.5) 0.053 24 (58.5) 77 (74.8) 0.055
pN1–2 32 (28.8) 11 (32.4) 20 (40.0) 23 (24.5) 17 (41.5) 26 (25.2)
Tumour grade
G1–2 93 (71.5) 29 (49.2) 0.003 37 (53.6) 85 (71.4) 0.014 29 (43.3) 93 (76.9) o0.001
G3 37 (28.5) 30 (50.8) 32 (46.4) 34 (28.6) 38 (56.7) 28 (23.1)
Vascular invasion
Present 8 (6.1) 9 (15.0) 0.045 12 (17.4) 5 (4.1) 0.002 12 (17.7) 5 (4.1) 0.002
Absent 123 (93.9) 51 (85.0) 57 (82.6) 116 (95.9) 56 (82.4) 117 (95.9)
Survival rate (%) (95%CI)
5 years 75.0 (62–84) 52.9 (36–67) 0.003 49.4 (30–66) 77.1 (66–85) 0.031 43.8 (26–60) 81.5 (69–89) o0.001
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sdiscriminatory ability for identifying survivors and non-survivors
at 5-year follow up compared with tumour budding or CD8þ
lymphocytes count themselves. More specifically, patients with a
low CD8þ lymphocyte:buds index have more than four-fold odds
of death at 5 years compared with a three-fold or under two-fold
risk for patients with low CD8þ counts or high number of tumour
buds, respectively. In addition, the CD8þ/buds index maintained
its significant impact on outcome in patients with stage II disease,
TNM stage II; P=0.019
High CD8+/buds index
(n=37; 2 deaths)
Low CD8+/buds index
(n=19; 5 deaths)
TNM stage III; P=0.004
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Figure 3 Cohort 2. Kaplan–Meier survival curves illustrating the poorer outcome in patients with a low CD8þ/buds index in (A) TNM stage II patients,
(B) TNM stage III patients, (C) patients not receiving adjuvant therapy and (D) patients treated with adjuvant therapy.
Table 7 Comparison of relative risks of buds, CD8+ and CD8þ/buds index in multivariable analysis with pN stage, vascular and lymphatic invasion and
adjuvant therapy in Cohort 2
Buds index only CD8+ index only CD8+/buds index
Cohort 2 HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Index
Low 1.0 0.029 1.0 0.473 1.0 0.005
High 1.96 (1.1–3.6) 0.79 (0.4–1.5) 0.39 (0.2–0.8)
pN stage
pN0 1.0 o0.001 1.0 o0.001 1.0 0.002
pN1–2 4.11 (1.8–9.2) 4.41 (2.0–9.7) 3.58 (1.6–7.9)
Vascular/lymphatic invasion
Absent 1.0 o0.001 1.0 0.006 1.0 0.007
Present 3.41 (1.7–7.1) 2.97 (1.4–6.4) 2.76 (1.3–5.7)
Adjuvant therapy
Untreated 1.0 0.057 1.0 0.068 1.0 0.076
Treated 0.5 (0.2–1.0) 0.52 (0.3–1.1) 0.53 (0.3–1.1)
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adjuvant therapy. Our previous work describes the absence of
tumour budding in cases with marked peritumoural inflammatory
reaction at the invasive margin of colorectal cancers and a strong
correlation between this inflammation and the presence of
TILs(Zlobec et al, 2007a). We hypothesised that an immune
response to colorectal cancer could account for an improved
prognosis in patients with abundant TIL count by specifically
targeting budding cells, a so-called ‘nipping in the bud’ effect
leading to improved prognosis. Although we cannot directly allude
to the functional interaction of CD8þ lymphocytes and tumour
budding in this study, our data nonetheless point to a strong link
between favourable prognosis and a high CD8þ lymphocyte:
tumour-budding index.
Several points in this study should still be considered. Although
the impact of tumour budding on clinical outcome is validated by
several groups, a standardised scoring system for this feature has
not yet been established, although several similar methods have
been proposed (Ueno et al, 2002; Shinto et al, 2005; Prall and
Ostwald, 2007). This study highlights a new approach, which may
be helpful in furthering the understanding of colorectal pathogen-
esis and prognosis, but requires validation by other research
groups both in retrospective and prospective settings. Finally, our
findings, particularly with regard to the test group may be
somewhat influenced by the lack of clinical information regarding
recurrence, metastasis and treatment although the majority of
clinico-pathological features are adequately covered.
On the other hand, several factors strongly support the validity of
our findings. The selection of parameters included in the proposed
index is evidence based, as both tumour budding and the CD8þ
lymphocytes have been tested and validated in colorectal cancer by
different research groups. The index, which encompasses a tumour-
and host-related feature, and therefore represents the more
advantageous ‘multi-marker’ approach to prognosis, better reflects
the tumour dynamic at the invasive front, compared with either
feature alone. This study also benefits from the inclusion of two
completely independent cohorts of colorectal cancer patients treated
in Switzerland and Greece, respectively. In addition to whole tissue
sections, we used the tissue microarray technique, a powerful tool
for the investigation of novel or potential biomarkers, which has
allowed us to evaluate hundreds of tissue cores for CD8þ.
Moreover, the evaluation of multiple tissue punches per tumour in
this study exceeds the number of cores required for adequate
representativity of tumour heterogeneity (Goethals et al,2 0 0 6 ) .
Although double staining was carried out for Cohort 1, only
immunohistochemistry for CD8 was carried out on Cohort 2. These
differences in methodology were chosen based on the ease of
identification of buds. In whole tissue sections, budding can often be
missed because of peritumoural inflammation, whereas tissue
microarrays may aid the observer to focus on one specific area
containing tumour buds. It is important to note that the independent
prognostic effects of the CD8þ/buds index were found in both sub-
groups despite the different laboratory circumstances and meth-
odologies, thereby underlining the biological consistency of the
CD8þ/buds index in colorectal cancer. Although we recognise that
this particular index is unlikely to be a final solution for daily
diagnostic practice, it may however serve as a basis that can be
further extended to include other strong and validated ‘pro-tumour’
or ‘anti-tumour’. This approach could potentially lead to a new
colorectal cancer prognostic score, which can be applied in addition
to TNM staging, as is the case for the BRE score for breast cancers.
In conclusion, the CD8þ lymphocyte to tumour-budding index
is an independent prognostic factor in colorectal cancer and
represents biologically a ‘pro-/anti-tumour’ model that could be a
promising approach for a future prognostic score in colorectal
cancer.
ACKNOWLEDGEMENTS
This study is funded by the Krebsliga Beider Basel (IZ, LT and AL).
REFERENCES
Ali AA, McMillan DC, Matalka II, McNicol AM, McArdle CS (2004) Tumour
T-lymphocyte subset infiltration and tumour recurrence following
curative resection for colorectal cancer. Eur J Surg Oncol 30: 292–295
B a k e rK ,Z l o b e cI ,T o r n i l l oL ,T e r r a c c i a n oL ,J a s sJ R ,L u g l iA( 2 0 0 7 )D i f f e r e n t i a l
significance of tumour infiltrating lymphocytes in sporadic mismatch repair
deficient vs proficient colorectal cancers: a potential role for dysregulation of
the transforming growth factor-beta pathway. Eur J Cancer 43: 624–631
Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Opinion:
migrating cancer stem cells–an integrated concept of malignant tumour
progression. Nat Rev Cancer 5: 744–749
Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF,
McArdle CS (2005) The relationship between tumour T-lymphocyte
infiltration, the systemic inflammatory response and survival in patients
undergoing curative resection for colorectal cancer. Br J Cancer 92: 651–654
Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC, Menegaux F,
Rosenzwajg M, Lemoine F, Klatzmann D, Taieb J (2009) Identification
of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Gut 58: 520–529
Chiba T, Ohtani H, Mizoi T, Naito Y, Sato E, Nagura H, Ohuchi A, Ohuchi
K, Shiiba K, Kurokawa Y, Satomi S (2004) Intraepithelial CD8+ T-cell-
count becomes a prognostic factor after a longer follow-up period in
human colorectal carcinoma: possible association with suppression of
micrometastasis. Br J Cancer 91: 1711–1717
Choi HJ, Park KJ, Shin JS, Roh MS, Kwon HC, Lee HS (2007) Tumor
budding as a prognostic marker in stage-III rectal carcinoma. Int J
Colorectal Dis 22: 863–868
Compton C (2006) Prognostic Factors in Cancer. John Wiley & Sons Inc:
Hoboken, NJ, USA
Dadabayev AR, Sandel MH, Menon AG, Morreau H, Melief CJ, Offringa R,
van der Burg SH, Janssen-van Rhijn C, Ensink NG, Tollenaar RA, van de
Velde CJ, Kuppen PJ (2004) Dendritic cells in colorectal cancer correlate
with other tumor-infiltrating immune cells. Cancer Immunol Immun-
other 53: 978–986
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages
C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P,
Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density,
and location of immune cells within human colorectal tumors predict
clinical outcome. Science 313: 1960–1964
Goethals L, Perneel C, Debucquoy A, De Schutter H, Borghys D, Ectors N,
Geboes K, McBride WH, Haustermans KM (2006) A new approach to the
validation of tissue microarrays. J Pathol 208: 607–614
Greenson JK, Bonner JD, Ben-Yzhak O, Cohen HI, Miselevich I, Resnick
MB, Trougouboff P, Tomsho LD, Kim E, Low M, Almog R, Rennert G,
Gruber SB (2003) Phenotype of microsatellite unstable colorectal
carcinomas: well-differentiated and focally mucinous tumors and the
absence of dirty necrosis correlate with microsatellite instability. Am J
Surg Pathol 27: 563–570
Hase K, Shatney C, Johnson D, Trollope M, Vierra M (1993) Prognostic
value of tumor ‘budding’ in patients with colorectal cancer. Dis Colon
Rectum 36: 627–635
Ishikawa Y, Akishima-Fukasawa Y, Ito K, Akasaka Y, Yokoo T, Ishii T
(2008) Histopathologic determinants of regional lymph node metastasis
in early colorectal cancer. Cancer 112: 924–933
Jass JR, Atkin WS, Cuzick J, Bussey HJ, Morson BC, Northover JM,
Todd IP (1986) The grading of rectal cancer: historical perspectives
and a multivariate analysis of 447 cases. Histopathology 10:
437–459
Jass JR, Do KA, Simms LA, Iino H, Wynter C, Pillay SP, Searle J,
Radford-Smith G, Young J, Leggett B (1998) Morphology of sporadic
colorectal cancer with DNA replication errors. Gut 42: 673–679
Prognostic impact of CD8þ/tumour buds on colorectal cancer
A Lugli et al
1391
British Journal of Cancer (2009) 101(8), 1382–1392 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sJenkins MA, Hayashi S, O’Shea AM, Burgart LJ, Smyrk TC, Shimizu D,
Waring PM, Ruszkiewicz AR, Pollett AF, Redston M, Barker MA, Baron
JA, Casey GR, Dowty JG, Giles GG, Limburg P, Newcomb P, Young JP,
Walsh MD, Thibodeau SN, Lindor NM, Lemarchand L, Gallinger S, Haile
RW, Potter JD, Hopper JL, Jass JR (2007) Pathology features in Bethesda
guidelines predict colorectal cancer microsatellite instability: a popula-
tion-based study. Gastroenterology 133: 48–56
Kazama S, Watanabe T, Ajioka Y, Kanazawa T, Nagawa H (2006) Tumour
budding at the deepest invasive margin correlates with lymph node
metastasis in submucosal colorectal cancer detected by anticytokeratin
antibody CAM5.2. Br J Cancer 94: 293–298
Koch M, Beckhove P, Op den Winkel J, Autenrieth D, Wagner P,
Nummer D, Specht S, Antolovic D, Galindo L, Schmitz-Winnenthal
FH, Schirrmacher V, Buchler MW, Weitz J (2006) Tumor infiltrating T
lymphocytes in colorectal cancer: Tumor-selective activation and
cytotoxic activity in situ. Ann Surg 244: 986–992; discussion 992–3
Michael-Robinson JM, Biemer-Huttmann A, Purdie DM, Walsh MD, Simms
LA, Biden KG, Young JP, Leggett BA, Jass JR, Radford-Smith GL (2001)
Tumour infiltrating lymphocytes and apoptosis are independent features
in colorectal cancer stratified according to microsatellite instability
status. Gut 48: 360–366
Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H
(1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic
factor in human colorectal cancer. Cancer Res 58: 3491–3494
Nakamura T, Mitomi H, Kikuchi S, Ohtani Y, Sato K (2005) Evaluation of
the usefulness of tumor budding on the prediction of metastasis to the
lung and liver after curative excision of colorectal cancer. Hepatogastro-
enterology 52: 1432–1435
Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R,
Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P,
Cugnenc PH, Trajanoski Z, Fridman WH, Galon J (2005) Effector
memory T cells, early metastasis, and survival in colorectal cancer.
N Engl J Med 353: 2654–2666
Phillips SM, Banerjea A, Feakins R, Li SR, Bustin SA, Dorudi S (2004)
Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite
instability are activated and cytotoxic. Br J Surg 91: 469–475
Prall F (2007) Tumour budding in colorectal carcinoma. Histopathology 50:
151–162
Prall F, Ostwald C (2007) High-degree tumor budding and podia-formation
in sporadic colorectal carcinomas with K-ras gene mutations. Hum
Pathol 38: 1696–1702
Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM (1997)
Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal
cancer. J Pathol 182: 318–324
Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta
B (2009) Tumor-infiltrating FOXP3+ T regulatory cells show strong
prognostic significance in colorectal cancer. JC l i nO n c o l27: 186–192
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA,
Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S,
Chen YT, Ohtani H, Old LJ, Odunsi K (2005) Intraepithelial CD8+ tumor-
infiltrating lymphocytes and a high CD8+/regulatory T-cell ratio are
associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci
USA 102: 18538–18543
Shinto E, Mochizuki H, Ueno H, Matsubara O, Jass JR (2005) A novel
classification of tumour budding in colorectal cancer based on the
presence of cytoplasmic pseudo-fragments around budding foci.
Histopathology 47: 25–31
Spaderna S, Schmalhofer O, Hlubek F, Jung A, Kirchner T, Brabletz T
(2007) Epithelial-mesenchymal and mesenchymal-epithelial transitions
during cancer progression. Verh Dtsch Ges Pathol 91: 21–28
Ueno H, Mochizuki H, Hashiguchi Y, Hatsuse K, Fujimoto H, Hase K
(2004a) Predictors of extrahepatic recurrence after resection of colorectal
liver metastases. Br J Surg 91: 327–333
Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida S, Hase K,
Matsukuma S, Kanai T, Kurihara H, Ozawa K, Yoshimura K, Bekku S
(2004b) Risk factors for an adverse outcome in early invasive colorectal
carcinoma. Gastroenterology 127: 385–394
Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC (2002) Tumour
‘budding’ as an index to estimate the potential of aggressiveness in rectal
cancer. Histopathology 40: 127–132
Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J,
Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass
J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas
MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S (2004)
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal
cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer
Inst 96: 261–268
Wang LM, Kevans D, Mulcahy H, O’Sullivan J, Fennelly D, Hyland J,
O’Donoghue D, Sheahan K (2009) Tumor budding is a strong and
reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg
Pathol 33: 134–141
Zlobec I, Baker K, Minoo P, Jass JR, Terracciano L, Lugli A (2008)
Node-negative colorectal cancer at high risk of distant metastasis
identified by combined analysis of lymph node status, vascular invasion,
and Raf-1 kinase inhibitor protein expression. Clin Cancer Res 14:
143–148
Zlobec I, Lugli A, Baker K, Roth S, Minoo P, Hayashi S, Terracciano L,
Jass JR (2007a) Role of APAF-1, E-cadherin and peritumoral lymphocytic
infiltration in tumour budding in colorectal cancer. J Pathol 212:
260–268
Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A (2007b) Selec-
ting immunohistochemical cut-off scores for novel biomarkers
of progression and survival in colorectal cancer. J Clin Pathol 60:
1112–1116
Prognostic impact of CD8þ/tumour buds on colorectal cancer
A Lugli et al
1392
British Journal of Cancer (2009) 101(8), 1382–1392 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s